Apparatus
Perkinelmer Launches Industry-First Cell Analysis Solution
Accelerating and simplifying the development and manufacturing process of cell and gene therapies.
Core Tip: Accelerating and streamlining the development and manufacturing process of cell and gene therapies
By WorldHealth.com PerkinElmer, a technology company dedicated to creating a healthier world through innovation, has launched Cellaca® PLX Image Cell Analysis System, the industry's first benchtop platform that enables researchers to analyze and assess multiple critical quality attributes (CQA) of cell samples in a single automated workflow, including the analysis of cell properties, quality and quantity.
The cutting-edge Cellaca PLX system, designed by Nexcelom, a PerkinElmer company, combines the hardware, software, proven consumables and traceable data reporting capabilities of a state-of-the-art image-based cell analyser in a single unit that can be operated without complex calibration procedures or rigorous training requirements. To further enhance the customer experience, this proprietary solution is optimized with proven antibody kits from BioLegend, a PerkinElmer company.
This new product provides researchers with expanded options for CQA analysis of cell samples beyond flow cytometry and staining methods, which have historically required a variety of different instruments and assays for analysis. Through the integration of these features, the Cellaca PLX system enables researchers to simultaneously detect multiple markers in a single instrument (multiplex technology) and perform immunophenotyping and cell activity assays in seconds through an easy-to-use, modern user interface.
Cellaca(R) PLX Image Cytometer image cell analyser
Pharmaceutical companies are investing heavily in cell and gene therapy, yet one of the major challenges they face is how to evaluate complex cell samples to meet the enormous scientific demands and stringent regulatory requirements of their research and manufacturing processes," said Alan Fletcher, Senior Vice President, Life Sciences, PerkinElmer. We are still developing the Cellaca PLX Image Cytometer for therapeutic applications and we anticipate that it will be of great importance for downstream processes involved in CAR-T cell therapy research to streamline the phenotyping of immune cells."
Nexcelom, a PerkinElmer company, is a leading provider of automated cell counting technology and image cytometer products for cell analysis, including the existing Cellaca® MX high-throughput automated cell counter, which is widely used.
-
ApparatusNov 21, 2024
Clinical Approval For Colombotide Skb264 (Mk-2870) In Combination With Oxitinib
-
ApparatusNov 20, 2024
New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity
-
ApparatusNov 19, 2024
The Frontier Drug INT230-6 Has Shown Promising Therapeutic Results In Soft Tissue Sarcoma!
-
ApparatusNov 18, 2024
Heavyweight! First ADC Drug For Refractory Ovarian Cancer Receives Accelerated FDA Approval
-
ApparatusNov 17, 2024
Ovarian Cancer Heavyweight Cutting-Edge ADC Drug Elahere Proven Safe And Effective